Mattia Bonsignori

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
  2. ncbi HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
  3. ncbi Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
  4. ncbi HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
  5. ncbi Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
  6. ncbi Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
  7. ncbi Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
    S Munir Alam
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 87:1554-68. 2013
  8. ncbi Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012

Collaborators

Detail Information

Publications8

  1. ncbi Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
    ..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs...
  2. ncbi HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
    ..Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design...
  3. ncbi Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
    ..These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities...
  4. ncbi HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
    ..The inability to generate high titers of long-lived anti-envelope Abs is a major hurdle to overcome for the development of a successful HIV-1 vaccine...
  5. ncbi Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  6. ncbi Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  7. ncbi Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
    S Munir Alam
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 87:1554-68. 2013
    ..These results demonstrate that deletion of N-terminal residues in the RV144 A244 gp120 immunogen improves both envelope antigenicity and immunogenicity...
  8. ncbi Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
    ..No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials...